Is there a potential for novel, nasal pertussis vaccines?

INTRODUCTION

Pertussis, caused by , remains a major public health problem, despite high vaccination coverage. Furthermore, the disease incidence has increased recently, especially in countries that have switched from whole-cell to acellular pertussis vaccines.

AREAS COVERED

Here, we provide a state-of-the art summary of the reasons for the pertussis resurgence and discuss potential solutions using current vaccines and challenges for the development of novel vaccines. PubMed was searched for publications with the terms pertussis and vaccines. Many new vaccine candidates are proposed but most have not reached clinical development. Most of them induce strong systemic immune responses and protection in mice. However, since is a mucosal pathogen, albeit with systemic effects, local immunity may be crucial to prevent infection and transmission. Recent efforts have focused on vaccine candidates able to induce immunity in the nasal cavity, and one of them is currently in clinical development.

EXPERT COMMENTARY

New pertussis vaccines are needed to durably control the disease and circulation of . A major challenge is to prove efficacy against disease in randomized controlled trials, while it is feasible to provide evidence for prevention of infection, since asymptomatic carriage of is wide spread.